Literature DB >> 29387246

MicroRNA-138 targets SP1 to inhibit the proliferation, migration and invasion of hepatocellular carcinoma cells.

Chongzhong Liu1, Jiankang Zhu1, Fengyue Liu1, Yadong Wang1, Min Zhu1.   

Abstract

The identification of microRNAs (miRNAs/miRs) has enabled the improved understanding of the carcinogenesis and progression of hepatocellular carcinoma (HCC). miRNAs are small non-coding RNAs comprised of 19-24 nucleotides that regulate the expression of target genes. In the present study, miR-138 was demonstrated to be downregulated in human HCC tissues and cell lines. Restoration of miR-138 expression repressed the proliferation, migration and invasion of HCC cells. Furthermore, specificity protein 1 (SP1) was identified as a target gene of miR-138 in HCC using bioinformatics analysis, luciferase reporter assay, reverse transcription-quantitative polymerase chain reaction and western blot analysis. Knockdown of SP1 produced similar suppressive effects to those induced by miR-138 overexpression in HCC cells. These results indicate that miR-138 targeted SP1 to repress the growth, migration and invasion of HCC cells, and may therefore represent a therapeutic target in human HCC.

Entities:  

Keywords:  hepatocellular carcinoma; invasion; microRNA-138; migration; proliferation; specificity protein 1

Year:  2017        PMID: 29387246      PMCID: PMC5768080          DOI: 10.3892/ol.2017.7357

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

3.  MiR-138 induces renal carcinoma cell senescence by targeting EZH2 and is downregulated in human clear cell renal cell carcinoma.

Authors:  Jiaqian Liang; Yajing Zhang; Guosong Jiang; Zhouqiang Liu; Wei Xiang; Xuanyu Chen; Zhaohui Chen; Jun Zhao
Journal:  Oncol Res       Date:  2013       Impact factor: 5.574

Review 4.  Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion.

Authors:  Pei-Jer Chen; Junji Furuse; Kwang-Hyub Han; Chiun Hsu; Ho-Yeong Lim; Hanlim Moon; Shukui Qin; Sheng-Long Ye; Ee-Min Yeoh; Winnie Yeo
Journal:  Liver Int       Date:  2010-11       Impact factor: 5.828

5.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

Review 6.  Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties.

Authors:  Louis M Pelus; Seiji Fukuda
Journal:  Exp Hematol       Date:  2006-08       Impact factor: 3.084

7.  miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.

Authors:  Yi Gao; XiaoWu Fan; WeiNa Li; Wei Ping; Yu Deng; XiangNing Fu
Journal:  Biochem Biophys Res Commun       Date:  2014-02-28       Impact factor: 3.575

8.  MicroRNA-138 Regulates Metastatic Potential of Bladder Cancer Through ZEB2.

Authors:  De-Kang Sun; Jian-Ming Wang; Peng Zhang; Yong-Qiang Wang
Journal:  Cell Physiol Biochem       Date:  2015-12-07

9.  Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2.

Authors:  Limin Long; Guoqing Huang; Hongyi Zhu; Yonghong Guo; Youshuo Liu; Jirong Huo
Journal:  J Transl Med       Date:  2013-10-30       Impact factor: 5.531

10.  MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.

Authors:  Yang Liu; Yumei Li; Rui Wang; Shukui Qin; Jing Liu; Fang Su; Yan Yang; Fuyou Zhao; Zishu Wang; Qiong Wu
Journal:  J Exp Clin Cancer Res       Date:  2016-01-27
View more
  7 in total

1.  MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1.

Authors:  Haile Qiu; Gehong Zhang; Bin Song; Junmei Jia
Journal:  Exp Ther Med       Date:  2019-07-25       Impact factor: 2.751

Review 2.  The Role of MicroRNAs in Hepatocellular Carcinoma.

Authors:  Xin Xu; Yuquan Tao; Liang Shan; Rui Chen; Hongyuan Jiang; Zijun Qian; Feng Cai; Lifang Ma; Yongchun Yu
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

3.  Decreased expression of circ_0020397 in intracranial aneurysms may be contributing to decreased vascular smooth muscle cell proliferation via increased expression of miR-138 and subsequent decreased KDR expression.

Authors:  Yushe Wang; Yong Wang; Yu Li; Bin Wang; Zhuang Miao; Xianzhi Liu; Yuanyuan Ma
Journal:  Cell Adh Migr       Date:  2019-12       Impact factor: 3.405

4.  OIP5-AS1 contributes to tumorigenesis in hepatocellular carcinoma by miR-300/YY1-activated WNT pathway.

Authors:  Yu Wang; Lei Dou; Yun Qin; Huiyuan Yang; Peng Yan
Journal:  Cancer Cell Int       Date:  2020-09-09       Impact factor: 5.722

5.  Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.

Authors:  Taohui Zeng; Lin Luo; Yuye Huang; Xiaoli Ye; Jinhai Lin
Journal:  Biomed Res Int       Date:  2021-03-06       Impact factor: 3.411

6.  Down-regulation of the Sp1 transcription factor by an increase of microRNA-4497 in human placenta is associated with early recurrent miscarriage.

Authors:  Huaiyun Tang; Linqing Pan; Yun Xiong; Leilei Wang; Yugui Cui; Jiayin Liu; Lisha Tang
Journal:  Reprod Biol Endocrinol       Date:  2021-02-12       Impact factor: 5.211

7.  Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1.

Authors:  Jing Yang; Bo Li; Shuo Zhao; Hongyu Du; Yaming Du
Journal:  Onco Targets Ther       Date:  2020-07-07       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.